Connect your agent to akta.pro and build company lists like this across sectors and geos.
Ten US biotech companies facing reported financial distress or restructuring in Q3 2026, ranked by incident relevance. Compare liquidity pressures, program setbacks and restructuring developments.
— 3 are in or have emerged from bankruptcy sales — BioXcel filed for Chapter 11 with Teva as stalking horse, Sangamo sold assets to PTC and Lilly for 161 million dollars, and Sequoia Vaccines sold its IP for 335,000 dollars.
— 4 disclosed going-concern doubt or cash exhaustion — Summit Therapeutics, Werewolf, OS Therapies and 60 Degrees Pharma each flagged going-concern risk or near-term cash exhaustion.
— Failed programs drove several cases — Neumora had three Phase 3 failures and a 35% workforce cut, and Arpeggio shut down after its lead program failed.
Companies ranked 10 of 1010 companies with reported financial distress signals
Highest relevance score 5.8 of 10BioXcel Therapeutics, Elevated band, 3 distinct outlets
Going-concern warnings or imminent cash exhaustion 4 of 10Summit, Werewolf, OS Therapies and 60 Degrees Pharma
Editorial list Coverage: United States, companies Filter: Negative sentiment Window: Jul 1, 2026 – Sep 30, 2026 Ranked by: Incident relevance Source: akta.pro News Signals Compiled: Sep 30, 2026| # | Company name | Firmographics | Funding & investors | What company does | What happened & why | Sources |
|---|---|---|---|---|---|---|
| 01 | BioXcel Therapeutics bioxceltherapeutics.com Elevated | Founded 2017 New Haven, CT USA | $233M Last raise 2026 | BioXcel Therapeutics is a clinical-stage biopharmaceutical company using its proprietary NovareAI platform to re-innovate existing drugs, commercializing IGALMI for acute agitation in schizophrenia/bipolar disorder and developing pipeline candidates BXCL501 (multiple neuroscience indications) and BXCL701 (immuno-oncology). Neurology & CNS Specialty Pharmaceuticals |
BioXcel Therapeutics filed for Chapter 11 in Delaware on 27 August 2026 after running out of cash, naming Teva as stalking horse bidder for its neuroscience assets at 57.5 million dollars upfront, and its stock fell to about 18 cents. Why The coverage cites a 13.8 million dollar cash reserve, negative working capital, going-concern doubt and an Oaktree-affiliated lender deadline. |
3 sources · 3 outlets |
| 02 | Summit Therapeutics smmttx.com Elevated | Founded 2003 Miami, FL USA | $3.79B Last raise 2026 | Summit Therapeutics is a clinical-stage biopharmaceutical company developing ivonescimab, a first-in-class PD-1/VEGF bispecific antibody in-licensed from Akeso Inc., targeting non-small cell lung cancer and colorectal cancer across US, Canada, Europe, Japan, Latin America, Middle East, and Africa with an FDA PDUFA date of November 14, 2026. Antibody-Drug Conjugates (ADCs) & Antibody Conjugates |
Summit Therapeutics disclosed in July 2026 substantial doubt about its ability to continue as a going concern despite 690.7 million dollars of cash, after its stock fell 50% on an interim HARMONi-3 readout that missed a threshold. Why The coverage says its cash is insufficient to fund planned operations for at least a year, with H1 losses above 405 million dollars and an FDA decision due 14 November. |
3 sources · 3 outlets |
| 03 | Sequoia Vaccines, Inc sequoiasciences.com Elevated | Founded 2012 St Louis, MO USA | – | Sequoia Vaccines was a St. Louis-based clinical-stage pharmaceutical company developing vaccines to prevent bacterial infections, including urinary tract infections, alongside early-stage therapies for cancer and cystic fibrosis-associated lung infections. Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) |
Sequoia Vaccines sold its intellectual property assets for 335,000 dollars in bankruptcy, as reported on 29 September 2026, with over 220 shareholders, mostly in St. Louis. Why The coverage says it shifted to a urinary tract infection vaccine but failed to secure partnerships with major pharmaceutical companies. |
1 source |
| 04 | Neumora Therapeutics neumoratx.com Elevated | Founded 2020 Watertown, MA USA | $615M Last raise 2024 | Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric, neurodegenerative, and cardiometabolic disorders, supported by its Precision Toolbox platform; it is pre-revenue and trades on NASDAQ under NMRA. Neurology & Psychiatry (CNS) Pharmaceuticals |
Neumora Therapeutics reported 116.8 million dollars in cash at 30 June 2026, down from 182.5 million, after three Phase 3 failures of its depression drug navacaprant, a 35% workforce cut and a new CEO. Why Management says cash provides runway into the third quarter of 2027, against 80.7 million dollars of debt. |
1 source |
| 05 | Shuttle Pharmaceuticals shuttlepharma.com Elevated | Founded 2013 Rockville, MD USA | $36M Last raise 2026 | Shuttle Pharmaceuticals is a publicly traded micro-cap company operating an AI-driven drug discovery platform (Molecule.ai) and a Dogecoin mining subsidiary (United Dogecoin), targeting pharmaceutical researchers and digital asset accumulation through serial acquisitions and equity financings. Radiation Oncology Therapeutics & Radiosensitizers |
Shuttle Pharmaceuticals missed its 31 July 2026 deadline to file its quarterly report and received a Nasdaq noncompliance notice on 28 August, with 1.09 million dollars in cash and a 5.8 million dollar working capital deficit. Why The coverage says it faces a shareholder vote on a 9.55 million dollar PIPE financing that could dilute holders. |
1 source |
| 06 | OS Therapies ostherapies.com Elevated | Founded 2018 New York, NY USA | $64M Last raise 2026 | OS Therapies is a clinical-stage oncology company developing immunotherapies for osteosarcoma and other solid tumors. Its lead candidate, OST-HER2, uses a modified Listeria-based platform to stimulate immune responses against HER2-expressing cancer cells. Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) |
OS Therapies disclosed in August 2026 a going-concern warning with only 205,000 dollars in cash against 24 million dollars of projected costs, leaving a 9 million dollar funding gap. Why The coverage says its survival depends on September data for its OST-HER2 therapy and an FDA Type B meeting. |
1 source |
| 07 | 60 Degrees Pharma 60degreespharma.com Elevated | Founded 2010 Washington, DC USA | $16M Last raise 2026 | 60 Degrees Pharmaceuticals develops and commercializes medicines for infectious diseases. Its FDA-approved antimalarial ARAKODA contains tafenoquine, which it is also investigating for the treatment of babesiosis. Infectious Disease Specialty Pharmaceuticals (Non-vaccine) |
60 Degrees Pharmaceuticals reported a second-quarter 2026 net loss of 2.4 million dollars and warned its cash would run out by mid-September, with a going-concern warning. Why The coverage says its funding facilities are depleted and its future depends on interim Phase 2 babesiosis data due in late September. |
1 source |
| 08 | Sangamo Therapeutics sangamo.com Elevated | Founded 1995 Brisbane, CA USA | $601M Last raise 2026 | Sangamo Therapeutics develops genomic medicines using zinc-finger gene-editing technology, gene regulation and gene therapies for inherited diseases and neurological conditions, including Fabry disease and prion disease. Gene Therapy for Rare/Monogenic Diseases |
Sangamo Therapeutics, which filed for voluntary Chapter 11 in June 2026, agreed in August to sell its Fabry disease gene therapy assets to PTC Therapeutics for 111 million dollars and its prion disease program to Eli Lilly for 50 million. Why The coverage describes the sales as a divestiture of its remaining valuable assets after the bankruptcy filing, subject to court approval. |
1 source |
| 09 | Arpeggio Bio arpeggiobio.com Elevated | Founded 2017 Boulder USA | $60M Last raise 2025 | Arpeggio Bio is a preclinical-stage biotech using an AI-enabled transcriptomic screening platform to discover small-molecule therapeutics targeting transcription factors, with an initial pipeline focus on lung cancer. Transcriptomics-Driven Drug Discovery & Development |
Arpeggio Biosciences, an eight-year-old Boulder biotech that raised a 17 million dollar Series A, shut down in August 2026. Why The coverage says its Nrf2 lung cancer program failed because efficacy could not be separated from an off-target liability. |
1 source |
| 10 | Werewolf Therapeutics werewolftx.com Elevated | Founded 2017 Watertown, MA USA | $328M Last raise 2026 | Werewolf Therapeutics is a clinical-stage oncology biopharmaceutical company developing conditionally activated INDUKINE™ cytokine and INDUCER™ T cell engager therapeutics via its proprietary PREDATOR® protein engineering platform, targeting patients with advanced solid tumors. Cytokines, Interferons & Immunomodulatory Proteins |
Werewolf Therapeutics disclosed a going-concern warning in its second-quarter filing on 31 July 2026, with cash down to 22 million dollars from 46.5 million at the end of March, and its shares fell 16%. Why The coverage says Q2 net income came only from a 21 million dollar asset sale to Jazz Pharmaceuticals, masking ongoing cash burn. |
1 source |
This dashboard covers US biotech companies in akta.pro's Healthcare & Life Sciences sector facing financial distress in Q3 2026, from Chapter 11 filings and asset sales to going-concern warnings and shutdowns. Distress matters here because small drug developers depend on trial data, financings and short cash runways.
The ranked companies range from a bankrupt gene therapy developer to clinical-stage firms with going-concern warnings, so the codes below reflect several sub-industries rather than one.
This section describes the industry classification of the ranked companies, not the Financial Distress & Restructuring signal category the dashboard tracks.
NAICS and SIC are global standard industry classifications, shown as returned by akta.pro Company Data for the listed companies. The internal taxonomy is akta.pro's own industry tree: each code links to its akta.pro industry page, and the signal categories this page filters on are listed in the Methodology below.